Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

61. Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure?

Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? 29264576 2018 11 13 2472-1972 1 9 2017 Sep 01 Journal of the Endocrine Society J Endocr Soc Homozygous Resistance to Thyroid Hormone β : Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? 1203-1212 10.1210/js.2017-00204 Resistance to thyroid hormone β (RTH β ) due to homozygous THRB defects is exceptionally rare (...) , with only five kindreds reported worldwide. Cardiac dysfunction, which can be life-threatening, is recognized in the disorder. Here we describe the clinical, metabolic, ophthalmic, and cardiac findings in a 9-year-old boy harboring a biallelic THRB mutation (R243Q), along with biochemical, physiologic, and cardiac responses to carbimazole and triiodothyroacetic acid (TRIAC) therapy. The patient exhibits recognized features (goiter, nonsuppressed thyroid-stimulating hormone levels, upper respiratory

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

62. An Unusual Case of Metastatic Functional Thyroid Carcinoma With a Remarkable Treatment Response to Radioactive Iodine

An Unusual Case of Metastatic Functional Thyroid Carcinoma With a Remarkable Treatment Response to Radioactive Iodine 29264468 2018 11 13 2472-1972 1 12 2017 Dec 01 Journal of the Endocrine Society J Endocr Soc An Unusual Case of Metastatic Functional Thyroid Carcinoma With a Remarkable Treatment Response to Radioactive Iodine. 1440-1444 10.1210/js.2017-00296 Functional thyroid carcinoma is an unusual cause of thyrotoxicosis. We describe the clinical presentation and treatment of a patient (...) with thyrotoxicosis due to functional thyroid carcinoma and Graves disease, and discuss potential mechanisms causing the thyrotoxicosis. A 79-year-old woman with a remote history of hemithyroidectomy and current hyperthyroidism came to the hospital with upper and lower extremity weakness. Hospital evaluation revealed a suppressed thyroid-stimulating hormone (TSH) level, positive test for thyroid-stimulating immunoglobulins, as well as a thyroid nodule, lung masses, and a 4.4-cm gluteal mass. Fine-needle

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

63. Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) ? Benefit assessment according to § 35a Social Code Book V

Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) ? Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Vandetanib (Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.1; Status: 1 June 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A17-01 Vandetanib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-01 Version 1.1 Vandetanib (thyroid cancer) 1 June 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Vandetanib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

64. [Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) - Benefit assessment according to õ 35a Social Code Book V]

[Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) - Benefit assessment according to õ 35a Social Code Book V] Vandetanib (Schilddrüsenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-01 [Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) – Benefit assessment according to § 35a Social Code Book V] Vandetanib (Schilddrüsenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17 (...) -01 [Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) – Benefit assessment according to § 35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Vandetanib

Health Technology Assessment (HTA) Database.2017

65. Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb

Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb 29264536 2018 11 13 2472-1972 1 7 2017 Jul 01 Journal of the Endocrine Society J Endocr Soc Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb. 852-860 10.1210/js.2017-00182 The mechanisms of thymic hyperplasia in Graves disease and its involution after radioiodine (I-131) therapy remain unknown. To examine whether (...) computed tomography (CT) findings of the thymus in patients with Graves disease change before and 6 months after I-131 therapy and to elucidate factors that affect these changes. A retrospective, single-center study was conducted. Thymic and thyroid volumes and thymic density were measured on CT. The associations of thymic volume or density with the following factors before I-131 therapy were examined: age; serum triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone receptor antibody

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

66. Hypothalamic-Pituitary-Thyroid Axis Set Point Alterations Are Associated With Body Composition in Androgen-Deprived Men

Hypothalamic-Pituitary-Thyroid Axis Set Point Alterations Are Associated With Body Composition in Androgen-Deprived Men 29264538 2018 11 13 2472-1972 1 7 2017 Jul 01 Journal of the Endocrine Society J Endocr Soc Hypothalamic-Pituitary-Thyroid Axis Set Point Alterations Are Associated With Body Composition in Androgen-Deprived Men. 874-885 10.1210/js.2017-00057 Androgen deprivation therapy (ADT) given to men with prostate cancer is associated with metabolically adverse changes in body (...) composition leading to insulin resistance, but the underlying mechanisms are not fully understood. We investigated prospectively whether androgen deprivation or its consequences may be associated with alterations in thyroid function in men. We performed a prespecified secondary analysis of a prospective case control study. We prospectively followed men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age-matched controls (n = 29) for 12 months. We assessed secondary outcomes

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

67. Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement.

Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. Importance: The incidence of thyroid cancer detection has increased by 4.5% per year over the last 10 years, faster than for any other cancer, but without a corresponding change in the mortality rate. In 2013, the incidence rate of thyroid cancer in the United States was 15.3 cases per 100 000 persons. Most cases of thyroid cancer have a good prognosis; the 5-year survival rate for thyroid cancer overall (...) is 98.1%. Objective: To update the US Preventive Services Task Force (USPSTF) recommendation on screening for thyroid cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for thyroid cancer in asymptomatic adults, the diagnostic accuracy of screening (including neck palpation and ultrasound), and the benefits and harms of treatment of screen-detected thyroid cancer. Findings: The USPSTF found inadequate direct evidence on the benefits of screening

JAMA2017

68. Teprotumumab for Thyroid-Associated Ophthalmopathy.

Teprotumumab for Thyroid-Associated Ophthalmopathy. BACKGROUND: Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy. METHODS: We conducted (...) in the Clinical Activity Score (scores range from 0 to 7, with a score of ≥3 indicating active thyroid-associated ophthalmopathy) and a reduction of 2 mm or more in proptosis at week 24. Secondary end points, measured as continuous variables, included proptosis, the Clinical Activity Score, and results on the Graves' ophthalmopathy-specific quality-of-life questionnaire. Adverse events were assessed. RESULTS: In the intention-to-treat population, 29 of 42 patients who received teprotumumab (69%), as compared

NEJM2017 Full Text: Link to full Text with Trip Pro

69. Direct Estimation of Reference Intervals for Thyroid Parameters in the Republic of Srpska

Direct Estimation of Reference Intervals for Thyroid Parameters in the Republic of Srpska 28680357 2018 11 13 1452-8258 36 2 2017 Apr Journal of medical biochemistry J Med Biochem Direct Estimation of Reference Intervals for Thyroid Parameters in the Republic of Srpska. 137-144 10.1515/jomb-2017-0008 The aim of this study was to determine the reference values for thyrotropin (TSH), thyroid hormones (total and free thyroxine, T4 and fT4; total and free triiodothyronine, T3 and fT3 (...) ), thyroglobulin (Tg) and thyroid antibodies (thyroid peroxidase, TPOAb and thyroglobulin antibody, TgAb) in the population of the Republic of Srpska. A total of 250 euthyroid subjects were enrolled in this study. A direct method for choosing reference subjects was used to establish reference intervals. The hormones and thyroid antibodies were measured by an electrochemiluminescence immunoassay method (ECLIA, Roche Diagnostics, Mannheim, Germany). We calculated the reference intervals by MedCalc, version

Journal of medical biochemistry2017 Full Text: Link to full Text with Trip Pro

70. Caprelsa for Medullary Thyroid Cancer – Details

Caprelsa for Medullary Thyroid Cancer – Details Caprelsa for Medullary Thyroid Cancer – Details | CADTH.ca Find the information you need Caprelsa for Medullary Thyroid Cancer – Details Caprelsa for Medullary Thyroid Cancer – Details Project Number pCODR 10090 Brand Name Caprelsa Generic Name Vandetanib Strength 100 mg and 300 mg tablets Tumour Type Endocrine Indication Medullary Thyroid Cancer Funding Request For the treatment of symptomatic and/or progressive medullary thyroid cancer in adult

CADTH - Pan Canadian Oncology Drug Review2017

71. Renal Transplant–Associated Thyroid Tuberculosis

Renal Transplant–Associated Thyroid Tuberculosis 29264509 2018 11 13 2472-1972 1 5 2017 May 01 Journal of the Endocrine Society J Endocr Soc Renal Transplant-Associated Thyroid Tuberculosis. 553-559 10.1210/js.2016-1058 Tuberculosis is common among solid-organ transplant recipients, including renal transplants. Tuberculosis of the thyroid gland is a rare diagnosis. We report on a renal transplant recipient with subacute fever associated with a neck mass diagnosed as thyroid tuberculosis (...) . No prior publication has reported a case of posttransplant thyroid tuberculosis. This is an important diagnostic consideration, in addition to malignant transformation, in the posttransplant setting. Levitt David L DL Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland 21201. Mesmar Bayan B Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

72. Effect of Vitamin D on Thyroid Autoimmunity: A Randomized, Double-Blind, Controlled Trial Among Ethnic Minorities

Effect of Vitamin D on Thyroid Autoimmunity: A Randomized, Double-Blind, Controlled Trial Among Ethnic Minorities 29264502 2018 11 13 2472-1972 1 5 2017 May 01 Journal of the Endocrine Society J Endocr Soc Effect of Vitamin D on Thyroid Autoimmunity: A Randomized, Double-Blind, Controlled Trial Among Ethnic Minorities. 470-479 10.1210/js.2017-00037 Autoimmune thyroid disorders have been linked to vitamin D deficiency, but an effect of vitamin D supplementation is not established. Our objective (...) was to test whether vitamin D compared with placebo could reduce thyroid autoantibodies. Predefined additional analyses from a randomized, double-blind, placebo-controlled trial. The study was conducted in different community centers in Oslo, Norway. A total of 251 presumed healthy men and women, aged 18 to 50 years, with backgrounds from South Asia, the Middle East, and Africa were included. Daily supplementation with 25 µg (1000 IU) vitamin D 3 , 10 µg (400 IU) vitamin D 3 , or placebo for 16 weeks

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

73. Rising Thyroid Cancer Incidence in Southern India: An Epidemic of Overdiagnosis?

Rising Thyroid Cancer Incidence in Southern India: An Epidemic of Overdiagnosis? 29264503 2018 11 13 2472-1972 1 5 2017 May 01 Journal of the Endocrine Society J Endocr Soc Rising Thyroid Cancer Incidence in Southern India: An Epidemic of Overdiagnosis? 480-487 10.1210/js.2017-00097 Thyroid cancer incidence is rising in high-income countries. This increase in disease burden is attributed to the phenomenon of overdiagnosis. We aimed to investigate trends in thyroid cancer rates in India (...) 100,000 women and the proportion of thyroid cancers diagnosed in females per 100 cancer cases. During 2006, the AARi for thyroid cancer in women in Thiruvananthapuram was 6.9 per 100,000, rising to 10 in 2009 and 13.3 in 2012. There was a 93% increase in incidence rates over less than a decade. The AARis in the other four cities were stable. In 2012, Thiruvananthapuram had at least a fourfold higher incidence compared with other regions. Thyroid was the primary site in one of every 10 cancers

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

74. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.

Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. Background The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older persons with this condition. Methods We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 (...) to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptoms score and Tiredness score on a thyroid-related

NEJM2017

75. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Importance: Thyroid cancer incidence has increased substantially in the United States over the last 4 decades, driven largely by increases in papillary thyroid cancer. It is unclear whether the increasing incidence of papillary thyroid cancer has been related to thyroid cancer mortality trends. Objective: To compare trends in thyroid cancer incidence and mortality by tumor characteristics at diagnosis. Design (...) , Setting, and Participants: Trends in thyroid cancer incidence and incidence-based mortality rates were evaluated using data from the Surveillance, Epidemiology, and End Results-9 (SEER-9) cancer registry program, and annual percent change in rates was calculated using log-linear regression. Exposure: Tumor characteristics. Main Outcomes and Measures: Annual percent changes in age-adjusted thyroid cancer incidence and incidence-based mortality rates by histologic type and SEER stage for cases diagnosed

JAMA2017

76. Pitfalls of exome sequencing: a case study of the attribution of HABP2 rs7080536 in familial non-medullary thyroid cancer

Pitfalls of exome sequencing: a case study of the attribution of HABP2 rs7080536 in familial non-medullary thyroid cancer 28884020 2018 11 13 2056-7944 2 2017 NPJ genomic medicine NPJ Genom Med Pitfalls of exome sequencing: a case study of the attribution of HABP2 rs7080536 in familial non-medullary thyroid cancer. 8 10.1038/s41525-017-0011-x Next-generation sequencing using exome capture is a common approach used for analysis of familial cancer syndromes. Despite the development of robust (...) sequence data, generously provided by the corresponding author, from a family with highly penetrant familial non-medullary thyroid cancer reported to be caused by HABP2 rs7080536 to review the importance of several key steps in the application of exome sequencing for discovery of new familial cancer genes. Differences in allele frequencies across populations, probabilities of familial segregation, functional impact predictions, corroborating biological support, and inconsistent replication studies can

NPJ genomic medicine2017 Full Text: Link to full Text with Trip Pro

77. Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells

Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells 28507479 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells. 354-362 10.17179/excli2017-113 Long non-coding RNAs (lncRNAs) have been found to show important regulatory roles in various human cancers. Lnc-RNA PANDAR is a novel identified lncRNA that was previously (...) reported to show abnormal expression pattern in various cancers. However, little is known of its expression and biological function in thyroid cancer. Here, we used the quantitative real-time PCR (qRT-PCR) to determine the expression of PANDAR in 64 thyroid cancer tissues. We found that expression of PANDAR was up-regulated in thyroid cancer tissues compared with adjacent non-tumor tissues. Functional assays in vitro demonstrated that knockdown of PANDAR could inhibit proliferation, cell cycle

EXCLI journal2017 Full Text: Link to full Text with Trip Pro

78. Concurrent Intrathyroidal Thyroid Cancer and Thyroid Cancer in Struma Ovarii: A Case Report and Literature Review

Concurrent Intrathyroidal Thyroid Cancer and Thyroid Cancer in Struma Ovarii: A Case Report and Literature Review 29264493 2018 11 13 2472-1972 1 5 2017 May 01 Journal of the Endocrine Society J Endocr Soc Concurrent Intrathyroidal Thyroid Cancer and Thyroid Cancer in Struma Ovarii: A Case Report and Literature Review. 396-400 10.1210/js.2017-00052 The presence of differentiated thyroid cancer in mature cystic teratomas in the ovaries is rare, and usually incidentally found on surgical (...) pathology specimens. We present a case of simultaneous intrathyroidal thyroid cancer and thyroid cancer within a struma ovarii, presenting specific diagnostic challenges. A 55-year-old woman had an intrathyroidal, encapsulated 1.2-cm papillary thyroid carcinoma, follicular variant, which was resected. Laboratory studies showed an elevated thyroglobulin level of 35 ng/mL while on suppressive levothyroxine therapy. During preparation for radioactive iodine ablation, thyroglobulin increased dramatically

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

79. Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer 29264486 2018 11 13 2472-1972 1 4 2017 Apr 01 Journal of the Endocrine Society J Endocr Soc Restoring Radioiodine Uptake in BRAF V600E- Mutated Papillary Thyroid Cancer. 285-287 10.1210/js.2016-1114 This image illustrates a multimodal therapeutic strategy for an iodine-refractory BRAF -mutated metastatic papillary thyroid carcinoma with reversed radioiodine resistance using BRAF inhibitors. Huillard Olivier O (...) Department of Medical Oncology. Tenenbaum Florence F Department of Nuclear Medicine, and. Clerc Jerome J Department of Nuclear Medicine, and. Goldwasser Francois F Department of Medical Oncology. Groussin Lionel L Department of Endocrinology, Hôpital Cochin, 75014, Paris, France, and. French Tumeurs de la Thyroïde Réfractaires TUTHYREF Network, 94800, Villejuif, France. eng Journal Article 2017 02 21 United States J Endocr Soc 101697997 2472-1972 BRAF mutation dabrafenib radioactive iodine thyroid cancer

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

80. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment.

Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. OBJECTIVE: To estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. DESIGN: Retrospective cohort study. SETTING: Large US administrative database between 1 January 2010 and 31 December 2014. PARTICIPANTS: 5405 pregnant women with subclinical hypothyroidism, defined as untreated thyroid stimulating hormone (TSH) concentration (...) 2.5-10 mIU/L. EXPOSURE: Thyroid hormone therapy. MAIN OUTCOME MEASURE: Pregnancy loss and other pre-specified maternal and fetal pregnancy related adverse outcomes. RESULTS: Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment TSH concentration of 4.8 (SD 1.7) mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 (SD 0.9) mIU/L were not treated (P<0.01). Pregnancy loss was significantly less common among treated women

BMJ2017 Full Text: Link to full Text with Trip Pro